UV and Ozone Plasma Decontamination with Ultrasound

Information

  • Research Project
  • 6503365
  • ApplicationId
    6503365
  • Core Project Number
    R43HL065081
  • Full Project Number
    3R43HL065081-01A1S1
  • Serial Number
    65081
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2001 - 23 years ago
  • Project End Date
    6/30/2002 - 22 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    7/1/2001 - 23 years ago
  • Budget End Date
    6/30/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
    A1S1
  • Award Notice Date
    9/27/2001 - 23 years ago
Organizations

UV and Ozone Plasma Decontamination with Ultrasound

DESCRIPTION (Provided from Applicant): The purpose of the proposed project is to develop an improved technology for the decontamination of human plasma, which is the straw-colored liquid that remains after all of the cellular components have been removed. Rich in clotting proteins and immune factors, plasma is used for direct transfusion for patients with severe bleeding and for the manufacture of more than 100 separate pharmaceutical components Plasma is also rich in nutrients, however, and thus often harbors infectious pathogens, notably viruses such as HIV and the various strains of hepatitis. To reduce the risk of spreading diseases through plasma or its concentrated components, several decontamination techniques have therefore been developed. Unfortunately, these techniques are often expensive, unable to treat non-enveloped viruses, require the pooling of thousands of plasma units, severely damage the plasma proteins or leave some residual toxic chemical additives. The proposed technological innovation is to use ultrasound to improve the performance of two conventional technologies, UV light exposure and ozone treatment. Because both of these techniques are known to be quite effective individually, their combined abilities should yield a quite safe product. The desired benefits of adding ultrasound to this combination include cheaper operation, improved processing speed and greater effectiveness. PROPOSED COMMERCIAL APPLICATION: Plasma and plasma products already comprise a multi-billion dollar industry. The commercial potential of this research is to provide this industry with a new, more effective and cheaper technique to decontaminate plasma. The products to be sold include an automated processor and its unique disposables.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    75372
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:75372\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CRYOFACETS, INC.
  • Organization Department
  • Organization DUNS
    799998955
  • Organization City
    RALEIGH
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    276137375
  • Organization District
    UNITED STATES